Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.

about

Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.

Item

http://www.wikidata.org/entity/Q54977783

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Clinical features of squamous ...... ospective analysis and review.

@en

Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase

@nl

type

Item

label

Clinical features of squamous ...... ospective analysis and review.

@en

Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase

@nl

prefLabel

Clinical features of squamous ...... ospective analysis and review.

@en

Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase

@nl

P1476

Clinical features of squamous ...... ospective analysis and review.

@en

P2093

Fuminori Sakurai

http://www.w3.org/2001/XMLSchema#string

Hiroaki Motomura

http://www.w3.org/2001/XMLSchema#string

Issei Sumiyoshi

http://www.w3.org/2001/XMLSchema#string

Junko Watanabe

http://www.w3.org/2001/XMLSchema#string

Kanae Abe

http://www.w3.org/2001/XMLSchema#string

Kazuhisa Takahashi

http://www.w3.org/2001/XMLSchema#string

Kentaro Suina

http://www.w3.org/2001/XMLSchema#string

Kotaro Kadoya

http://www.w3.org/2001/XMLSchema#string

Moe Iwai

http://www.w3.org/2001/XMLSchema#string

Shinichi Sasaki

http://www.w3.org/2001/XMLSchema#string

P2860

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy.

Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients

P304

24000-24013

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25257

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hiroyuki Mizuguchi

P577

2018-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29844868

http://www.w3.org/2001/XMLSchema#string

P932

5963613

http://www.w3.org/2001/XMLSchema#string